Sage Journals: Discover world-class research

Abstract

Cardiovascular autonomic diabetic neuropathy (CADN) is one of the most common diabetes-associated complications. Disturbed heart rate variability (HRV) is very often the earliest symptom, even in clinically asymptomatic patients. The following article offers a topical overview for those working or interested in the fields of diabetology and cardiology.

Keywords

autonomic nervous system cardiovascular disease risk diabetes mellitus heart rate variability vagus nerve

References

1. American Diabetes Association, American Academy of Neurology. Consensus statement: Report and recommendations of the San Antonio conference on diabetic neuropathy. Diabetes Care 1988;11:592–7.

2. Vinik AI Maser RE , Mitchell BD et al. Diabetic autonomic neuropathy. Diabetes Care 2003;26:1553–79.

3. Pfeifer MA Weinberg CR , Cook DL et al. Autonomic neural dysfunction in recently diagnosed diabetic subjects. Diabetes Care 1984;7:447–53.

4. Ziegler D Dannehl K , Mühlen H et al. Prevalence of cardiovascular autonomic dysfunction assessed by spectral analysis, vector analysis, and standard tests of heart rate variation and blood pressure responses at various stages of diabetic neuropathy. Diabet Med 1992;9:806–14.

5. Haslbeck M, Luft D, Neundörfer B et al. Diagnose, Therapie und Verlaufskontrolle der autonomen diabetischen Neuropathie. Evidenzbasierte Diabetes-Leitlinie DDG. Deutsche Diabetes-Gesellschaft. 1. Auflage 2002.

6. Maser RE Mitchell BD , Vinik AI et al. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes. A meta-analysis. Diabetes Care 2003;26:1895–901.

7. Ewing DJ Campbell IW , Clarke FB. The natural history of diabetic autonomic neuropathy. Q J Med 1980;49:95–108.

8. Watkins PJ Mackay DJ. Cardiac denervation in diabetic neuropathy. Ann Intern Med 1980;92:304–07.

9. Schrödter D. Diabetes mellitus – eine kardiovaskuläre Erkrankung. 1. Auflage. UNI-MED, Bremen 2002.

10.

10. Ewing DJ Campbell IW , Clarke FB. Heart rate changes in diabetes mellitus. Lancet 1981;317:183–6.

11.

11. DCCT Research Group. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia 1998;41:416–23.

12.

12. Kennedy WR Navarro X , Goetz FC et al. Effects of pancreatic transplantation on diabetic neuropathy. N Engl J Med 1990;322:1031–7.

13.

13. Kennedy WR Navarro X , Sutherland ED. Neuropathy profile of diabetic patients in a pancreas transplantation program. Neurology 1995;45:773–80.

14.

14. Luft D. Praxisleitfaden der diabetischen Polyneuropathie. 1. Auflage. UNI-MED Verlag, Bremen 2000.

15.

15. Ewing DJ Campbell IW , Clarke FB. Mortality in diabetic autonomic neuropathy. Lancet 1976;1:601–03.

16.

16. Gerritsen J Dekker JM , TenVoorde BJ et al. Impaired autonomic function is associated with increased mortality, especially in subjects with diabetes, hypertension, or a history of cardiovascular disease. The HOORN Study. Diabetes Care 2001;24:1793–8.

17.

17. Navarro X Kennedy WR , Aeppli D et al. Neuropathy and mortality in diabetes: influence of pancreas transplantation. Muscle Nerve 1996;19:1009–16.

18.

18. Katz A Liberty IF , Porath A et al. A simple bedside test of 1-minute heart rate variability during deep breathing as a prognostic index after myocardial infarction. Am Heart J 1999;138:32–8.

19.

19. Valensi P Sachs RN , Harfouche B et al. Predictive value of cardiac autonomic neuropathy in diabetic patients with or without silent myocardial ischemia. Diabetes Care 2001;24:339–43.

20.

20. O'Brien IA , O'Hare JP , Lewin IG et al. The prevalence of autonomic neuropathy in insulin-dependent diabetes mellitus: a controlled study based on heart rate variability. Q J Med 1986;61:957–67.

21.

21. Clarke BF Ewing DJ , Campbell WI. Diabetic autonomic neuropathy. Diabetologia 1979;17:195–212.

22.

22. Maser RE Pfeifer MA , Dorman JS et al. Diabetic autonomic neuropathy and cardiovascular risk. Pittsburgh Epidemiology of Diabetes Complications Study III. Arch Intern Med 1990;150:1218–22.

23.

23. Cohen JA Jeffers BW , Faldut D et al. Risks for sensorimotor peripheral neuropathy and autonomic neuropathy in non-insulin-dependent diabetes mellitus (NIDDM). Muscle Nerve 1998;21:72–80.

24.

24. Spallone V Maiello MR , Cicconetti E et al. Autonomic neuropathy and cardiovascular risk factors in insulin-dependent and non-insulin-dependent diabetes. Diabetes Res Clin Pract 1997;34:169–79.

25.

25. Colhoun HM Francis DP , Rubens MB et al. The association of heart-rate variability with cardiovascular risk factors and coronary artery calcification: A study in type 1 diabetic patients and the general population. Diabetes Care 2001;24:1108–14.

26.

26. Simonson DC. Etiology and prevalence of hypertension in diabetic patients. Diabetes Care 1988;11:812–27.

27.

27. Muller JE Tofler GH , Stone HP. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989;79:733–43.

28.

28. The Task Force of the European Society of Cardiology and the North American Society of Pacing Electrophysiology [ESC and NASPE]. Heart rate variability – standards of measurement, physiological interpretation and clinical use. Circulation 1996;93:1043–65.

29.

29. Esperer HD. Physiologische Grundlagen und pathologische Aspekte der Herzfrequenzvariabilität beim Menschen. Herzschr Elektrophys 1994;5(suppl 2):1–10.

30.

30. Karemaker JM Lie IK. Heart rate variability: a telltale of health or disease. Editorial. Eur Heart J 2000;21:435–7.

31.

31. Cheng TO. Decreased heart rate variability as a predictor for sudden death was known in China in the third century A.D. Letter to the editor. Eur Heart J 2000;21:2081–2.

32.

32. Scherer P. Parameter der Herzfrequenzvariabilität im Zeitbereich. Herzschr Elektrophys 1994;5:15–18.

33.

33. Ewing DJ Martyn CN , Young RJ et al. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care 1985;8(suppl 2):491–8.

34.

34. Meesmann M Boese J , Scharf R. Vergleich der Methoden zur Bestimmung der Herzfrequenzvariabilität. Herzschr Elektrophys 1994;5(suppl 2):25–9.

35.

35. Wegschneider K. Statistische Zeitreihenmodelle und Herzfrequenzvariabilität. Herzschr Elektrophys 1994;5(suppl 2):11–14.

36.

36. Walbrecht P Cohen JR. Estimation of heart rate power spectrum bands from real-world data: dealing with ectopic beats and noisy data. Comput Cardiol 1988;15:311–14.

37.

37. Howorka K Pumprla J , Schabmann A. Optimal parameters of short-term heart rate spectrogram for routine evaluation of diabetic cardiovascular autonomic neuropathy. J Auton Nerv Syst 1998;69:104–72.

38.

38. Bigger JT Jr , Fleiss JL , Rolnitzky LM et al. Stability over time of heart period variability in patients with previous myocardial infarction and ventricular arrhythmias. The CAPS and ESVEM investigators. Am J Cardiol 1992;69:718–23.

39.

39. Akselrod S Gordon D , Ubel FA et al. Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control. Science 1981;213:220–2.

40.

40. Pomeranz B Macaulay RJ , Caudill MA et al. Assessment of autonomic function in humans by heart rate spectral analysis. Am J Physiol 1985;248:H151–H153.

41.

41. Rimoldi O Pierini S , Ferrari A et al. Analysis of short-term oscillations of R-R and arterial pressure in conscious dogs. Am J Physiol 1990;258:H967–H976.

42.

42. Montano N Ruscone TG , Porta A et al. Power spectrum analysis of heart rate variability to assess the changes in sympathovagal balance during graded orthostatic tilt. Circulation 1994;90:1826–31.

43.

43. Hayano J Sakakibara Y , Yamada A et al. Accuracy of assessment of cardiac vagal tone by heart rate variability in normal subjects. Am J Cardiol 1991;67:199–204.

44.

44. Malliani A Pagani M , Lombardi F et al. Cardiovascular neural regulation explored in the frequency domain. Circulation 1991;84:1482–92.

45.

45. Hedman AE Tahvanainen KU , Hartikainen JE et al. Effect of sympathetic modulation and sympatho-vagal interaction on heart rate variability in anaesthetized dogs. Acta Physiol Scand 1995;155:205–14.

46.

46. Pagani M Lombardi F , Guzzetti S et al. Power spectral density of heart rate variability as an index of sympatho-vagal interaction in normal and hypertensive subjects. J Hypertens 1984;2(suppl):S383–S385.

47.

47. Kamath MV Ghista DN , Fallen EL et al. Heart rate variability power spectrogram as a potential non-invasive signature of cardiac regulatory system response, mechanisms, and disorders. Heart Vessels 1987;3:33–41.

48.

48. Sroka K. Vagale Depression und ischämische Herzkrankheit. Herz Kreisl 1998;30:437–43.

49.

49. Brüggemann T , Weiß D , Andresen D. Spektralanalyse zur Beurteilung der Herzfrequenzvariabilität. Herzschr Elektrophys 1994;5(suppl 2): 19–24.

50.

50. Bigger JT Jr , Fleiss JL , Steinman RC et al. Frequency domain measures of heart period variability and mortality after myocardial infarction. Circulation 1992;85:164–71.

51.

51. Tsuji H Venditti Jr FJ , Manders ES et al. Reduced heart rate variability and mortality risk in an elderly cohort. Circulation 1994;90:878–83.

52.

52. Pagani M. Heart rate variability and autonomic diabetic neuropathy. Diabetes Nutr Metab 2000;13:341–6.

53.

53. Rathmann W Ziegler D , Jahnke M et al. Mortality in diabetic patients with cardiovascular autonomic neuropathy. Diabet Med 1993;10:664–71.

54.

54. Wolf MM Varigos GA , Hunt D et al. Sinus arrhythmia in acute myocardial infarction. Med J Aust 1978;2:52–3.

55.

55. Nolan J Batin PD , Andrews R et al. Results of the United Kingdom Heart Failure Evaluation and Assessment of Risk Trial (UK-Heart). Circulation 1998;98:1510–16.

56.

56. Kleiger RE Miller JP , Bigger JT Jr et al. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987;59:256–62.

57.

57. Malik M Farrell T , Cripps T et al. Heart rate variability in relation to prognosis after myocardial infarction: selection of optimal processing techniques. Eur Heart J 1989;10:1060–74.

58.

58. Cripps TR Malik M , Farrell TG et al. Prognostic value of reduced heart rate variability after myocardial infarction: clinical evaluation of a new analysis method. Br Heart J 1991;65:14–19.

59.

59. La Rovere MT , Bigger JT Jr , Marcus FI et al. Baroreflex sensitivity and heartrate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet 1998;351:478–84.

60.

60. Ponikowski P Anker SD , Chua TP et al. Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1997;79:1645–50.

61.

61. Makikallio TH Huikuri HV , Hintze U et al. Fractal analysis and time and frequency-domain measures of heart rate variability as predictors of mortality in patients with heart failure. Am J Cardiol 2001;87:178–82.

62.

62. Klingenheben T Credner S , Grönefeld G et al. Kardialer autonomer Tonus zur Risikostratifikation nach Myokardinfarkt: Ergebnisse einer prospektiven Langzeitstudie bei 411 konsekutiven Patienten. Z Kardiol 1999;88:400–09.

63.

63. De Ferrari GM , Vanoli E , Curcuruto P et al. Prevention of life-threatening arrhythmias by pharmacologic stimulation of the muscarinic receptors with oxotremorine. Am Heart J 1992;124:883–90.

64.

64. Gold DR Litonjua A , Schwartz J et al. Ambient pollution and heart rate variability. Circulation 2000;101:1267–73.

65.

65. Roche F Gaspoz JM , Court-Fortune I et al. Screening of obstructive sleep apnea syndrome by heart rate variability analysis. Circulation 1999;100:1411–15.

66.

66. Kazuma N Otsuka K , Matsuoka I et al. Heart rate variability during 24 hours in asthmatic children. Chronobiol Int 1997;14:597–606.

67.

67. Coelho L Saraiva S , Guimaraes H et al. Autonomic function in chronic liver disease assessed by Heart Rate Variability Study. Rev Port Cardiol 2001;20:25–36.

68.

68. Leicht AS Allen GD , Hoey JA. Influence of intensive cycling training on heart rate variability during rest and exercise. Can J Appl Physiol 2003;28:898–909.

69.

69. Garet M Tournaire N , Roche F et al. Individual interdependence between nocturnal ANS activity and performance in swimmers. Med Sci Sports Exerc 2004;36:2112–18.

70.

70. Agelink MW Malessa R , Baumann B et al. Standardised tests of heart rate variability: normal ranges obtained from 309 healthy humans, and effects of age, gender, and heart rate. Clin Auton Res 2001;11:99–108.

71.

71. Ziegler D Laux G , Dannehl K et al. Assessment of cardiovascular autonomic function: age-related normal ranges and reproducibility of spectral analysis, vector analysis, and standard tests of heart rate variation and blood pressure responses. Diabet Med 1992;9:166–75.

72.

72. Evans JM Ziegler MG , Patwardhan AR et al. Gender differences in autonomic cardiovascular regulation: spectral, hormonal, and hemodynamic indexes. J Appl Physiol 2001;91:2611–18.

73.

73. Wawryk AM Bates DJ , Couper JJ. Power spectral analysis of heart rate variability in children and adolescents with IDDM. Diabetes Care 1997;20:1416–21.

74.

74. Ziegler D Gries FA , Spüler M et al. The epidemiology of diabetic neuropathy. Diabetic Cardiovascular Autonomic Neuropathy Multicenter Study Group. J Diabetes Complications 1992;6:49–57.

75.

75. Chessa M Butera G , Lanza GA et al. Role of heart rate variability in the early diagnosis of diabetic autonomic neuropathy in children. Herz 2002;27:785–90.

76.

76. Levitt NS Stansberry KB , Wynchank S et al. The natural progression of autonomic neuropathy and autonomic function tests in a cohort of people with IDDM. Diabetes Care 1996;19:751–4.

77.

77. Howorka K Pumprla J , Haber P et al. Effects of physical training on heart rate variability in diabetic patients with various degrees of cardiovascular autonomic neuropathy. Cardiovasc Res 1997;34:206–14.

78.

78. Singh JP Larson MG , O'Donnell CJ et al. Association of hyperglycemia with reduced heart rate variability (The Framingham Heart Study). Am J Cardiol 2000;86:309–12.

79.

79. DCCT Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial (DCCT). Diabetes 1996;45:1289–98.

80.

80. Gaede P Vedel P , Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383–93.

81.

81. Ziegler D Schatz H , Conrad F et al. Effects of treatment with the antioxidant α-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. Diabetes Care 1997;20:369–73.

82.

82. Didangelos TP Karamitsos DT , Athyros VG et al. Effect of aldose reductase inhibition on cardiovascular reflex tests in patients with definite diabetic autonomic neuropathy over a period of 2 years. J Diabetes Complications 1998;12:201–07.

83.

83. Okamoto H Nomura M , Nakaya Y et al. Effects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesis. Intern Med 2003;42:655–64.

84.

84. Kontopoulos AG Athyros VG , Didangelos TP et al. Effect of chronic quinapril administration on heart rate variability in patients with diabetic autonomic neuropathy. Diabetes Care 1997;20:355–61.

85.

85. Malik RA Williamson S , Abbott C et al. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 1998;352:1978–81.

86.

86. Ebbehoj E Poulsen PL , Hansen KW et al. Effects on heart rate variability of metoprolol supplementary to ongoing ACE-inhibitor treatment in type I diabetic patients with abnormal albuminuria. Diabetologia 2002;45:965–75.

87.

87. Gaede P second author, third author et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2008;358:580–58.

88.

88. Tesfaye S Chaturvedi N , Eaton SEM et al. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005;352:341–50.

89.

89. Schönauer M , Schreiner M , Niebauer J et al. Einfluss der Stoffwechselverbesserung unter Pioglitazon auf die Herzfrequenzvariabilität bei Typ-2-Diabetikern: Ergebnisse der Praxisstudie ETAPP. Dtsch Ärztebl Thüringen 2004;15:340–1.

90.

90. Kautz, C , Thomas A. Kardiale autonome diabetische Neuropathie. Diabetologie Stoffwechsel 2007;2:175–82.

91.

91. Eiskjar N Weston P J , Bush G et al. A pocket size device to detect autonomic neuropathy. J Diabetes Sci Technol 2008;4:692–6.

92.

92. Boulton AJM Vinik AI , Arezzo JC et al. Diabetic neuropathies, A statement by the American Diabetes Association. Diabetes Care 2005;28:956–62.

Cardiac autonomic diabetic neuropathy

Abstract

Keywords

References